Ipsen announced a voluntary withdrawal of Tazverik (tazemetostat) from the market and halted ongoing clinical studies after an independent data monitoring committee identified cases of secondary hematologic malignancies in a confirmatory trial in follicular lymphoma. The company said it will ensure trial participants receive standard‑of‑care treatment and continue safety monitoring. Tazverik was originally developed by Epizyme and later became part of Ipsen’s portfolio following acquisition. Regulators, payers and other developers of epigenetic therapies will monitor the safety review closely; industry sources cautioned that the withdrawal could affect commercial projections but is not expected to materially alter Ipsen’s broader financial guidance.